Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
Valente, Susana Tereno
Display my h-index
Publications in VIVO
 
    Export Publications Table
co-author
Co-author Network
map of science
Map of Science
Biosketch in .docx format  Create Biosketch

Valente, Susana Tereno

Faculty Member
share the uri qr icon Close

Positions

  • 2019 - Associate Professor Tenure, Immunology and Microbiology , Scripps Research
  • 2009 - Faculty Member, Skaggs Graduate School of Chemical and Biological Sciences , Scripps Research
  • 2017 - 2019 Associate Professor, Immunology and Microbiology , Scripps Research
  • 2009 - 2017 Assistant Professor, Immunology and Microbial Science (IMS) , Scripps Research
  • 2012 - 2015 Assistant Professor, Infectious Diseases , Scripps Research
  • 2009 - 2012 Assistant Professor, Infectology , Scripps Research
  • 2009 Research Fellow, Columbia University
Dr. Susana Valente focuses on the discovery and characterization of molecular interactions occurring within a host cell that are critical for HIV replication - the interactions so identified can be tailored to develop therapeutic targets and provide novel antiviral approaches.

Contact

  • svalente@scripps.edu

Websites

  • Susana Tereno Valente, Ph.D.
  • Laboratory Website
  • Publications
  • Research
  • Teaching
  • Background
  • Contact
  • View All
scroll to property group menus

Publications

recent publications
  • All Publications
  • PubMed Display for Export
  • Publications without PubMed PMIDs

  • academic article

    • Mediouni, S., Jablonski, J. A., Tsuda, S., Barsamian, A., Kessing, C., Richard, A., Biswas, A., Toledo, F., Andrade, V. M., Even, Y., Stevenson, M., Tellinghuisen, T., et al. Oregano Oil and Its Principal Component, Carvacrol, Inhibit HIV-1 Fusion into Target Cells Journal of Virology  2020 94  DOI:10.1128/jvi.00147-20  PMID:32461309  PMCID:PMC7375364
    • Patki, M., Vartak, R., Jablonski, J., Mediouni, S., Gandhi, T., Fu, Y. G., Cetindag, E., Dave, R., Valente, S. T., Patel, K. Efavirenz nanomicelles loaded vaginal film (EZ film) for preexposure prophylaxis (PrEP) of HIV Colloids and Surfaces B-Biointerfaces  2020 194  DOI:10.1016/j.colsurfb.2020.111174  PMID:32540766
    • Mori, L., Valente, S. T. Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure Viruses  2020 12  DOI:10.3390/v12050529  PMID:32403278  PMCID:PMC7291152
    • Mousseau, G., Aneja, R., Clementz, M. A., Mediouni, S., Lima, N. S., Haregot, A., Kessing, C. F., Jablonski, J. A., Thenin-Houssier, S., Nagarsheth, N., Trautmann, L., Valente, S. T. Resistance to the Tat inhibitor didehydro-cortistatin a is mediated by heightened basal HIV-1 transcription MBio  2019 10:e01750-18  DOI:10.1128/mBio.01750-18  PMID:31266880  PMCID:PMC6606815
    • Mediouni, S., Kessing, C. F., Jablonski, J. A., Thenin-Houssier, S., Clementz, M., Kovach, M. D., Mousseau, G., de Vera, I. M. S., Li, C., Kojetin, D. J., Evans, D. T., Valente, S. T. The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation FASEB Journal  2019 33:8280-8293  DOI:10.1096/fj.201801165R  PMID:31021670  PMCID:PMC6593873
    • Takata, H., Kessing, C., Sy, A., Lima, N., Sciumbata, J., Mori, L., Jones, R. B., Chomont, N., Michael, N. L., Valente, S., Trautmann, L. Modeling HIV-1 latency using primary CD4(+) T cells from virally suppressed HIV-1-infected individuals on antiretroviral therapy Journal of Virology  2019 93:e02248-18  DOI:10.1128/jvi.02248-18  PMID:30918072
    • Li, C., Mousseau, G., Valente, S. T. Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat Epigenetics & Chromatin  2019 12  DOI:10.1186/s13072-019-0267-8  PMID:30992052  PMCID:PMC6466689
    • Mediouni, S., Chinthalapudi, K., Ekka, M. K., Usui, I., Jablonski, J. A., Clementz, M. A., Mousseau, G., Nowak, J., Macherla, V. R., Beverage, J. N., Esquenazi, E., Baran, P., et al. Didehydro-cortistatin A inhibits HIV-1 by specifically binding to the unstructured basic region of Tat MBio  2019 10:e02662-18  DOI:10.1128/mBio.02662-18  PMID:30723126  PMCID:PMC6368365
    • Mediouni, S., Jablonski, J. A., Tsuda, S., Richard, A., Kessing, C., Andrade, M. V., Biswas, A., Even, Y., Tellinghuisen, T., Choe, H., Cameron, M., Stevenson, M., et al. Potent suppression of HIV-1 cell attachment by Kudzu root extract Retrovirology  2018 15  DOI:10.1186/s12977-018-0446-x  PMID:30236131  PMCID:PMC6149077
    • Kessing, C. F., Nixon, C. C., Li, C., Tsai, P., Takata, H., Mousseau, G., Ho, P. T., Honeycutt, J. B., Fallahi, M., Trautmann, L., Garcia, J. V., Valente, S. T. In vivo suppression of HIV rebound by didehydro-Cortistatin A, a "block-and-lock'' strategy for HIV-1 treatment Cell Reports  2017 21:600-611  DOI:10.1016/j.celrep.2017.09.080  PMID:29045830  PMCID:PMC5653276
    • Mousseau, G., Valente, S. T. Role of host factors on the regulation of Tat-mediated HIV-1 transcription Current Pharmaceutical Design  2017 23:4079-4090  DOI:10.2174/1381612823666170622104355  PMID:28641539
    • Wu, H., Mousseau, G., Mediouni, S., Valente, S. T., Kodadek, T. Cell-permeable peptides containing cycloalanine residues Angewandte Chemie-International Edition  2016 55:12637-12642  DOI:10.1002/anie.201605745  PMID:27529332
    • Deeks, S. G., Lewin, S. R., Ross, A. L., Ananworanich, J., Benkirane, M., Cannon, P., Chomont, N., Douek, D., Lifson, J. D., Lo, Y. R., Kuritzkes, D., Margolis, D., et al. International AIDS Society global scientific strategy: towards an HIV cure 2016 Nature Medicine  2016 22:839-850  DOI:10.1038/nm.4108  PMID:27400264
    • Thenin-Houssier, S., de Vera, I. M. S., Pedro-Rosa, L., Brady, A., Richard, A., Konnick, B., Opp, S., Buffone, C., Fuhrmann, J., Kota, S., Billack, B., Pietka-Ottlik, M., et al. Ebselen, a small-molecule capsid inhibitor of HIV-1 replication Antimicrobial Agents and Chemotherapy  2016 60:2195-2208  DOI:10.1128/aac.02574-15  PMID:26810656  PMCID:PMC4808204
    • Mousseau, G., Valente, S. T. Didehydro-Cortistatin A: a new player in HIV-therapy? Expert Review of Anti-Infective Therapy  2016 14:145-148  DOI:10.1586/14787210.2016.1122525  PMID:26581953  PMCID:PMC4793404
    • Thenin-Houssier, S., Valente, S. T. HIV-1 capsid inhibitors as antiretroviral agents Current HIV Research  2016 14:270-282  DOI:10.2174/1570162x14999160224103555  PMID:26957201  PMCID:PMC4785820
    • Mediouni, S., Marcondes, M. C. G., Miller, C., McLaughlin, J. P., Valente, S. T. The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders Frontiers in Microbiology  2015 6:1164  DOI:10.3389/fmicb.2015.01164  PMID:26557111  PMCID:PMC4615951
    • Mousseau, G., Kessing, C., Fromentin, R., Trautmann, L., Chomont, N., Valente, S. T. The Tat inhibitor didehydro-Cortistatin A prevents HIV-1 reactivation from latency MBio  2015 3:e00465  DOI:10.1128/mBio.00465-15  PMID:26152583  PMCID:PMC4495168
    • Mousseau, G., Kessing, C. F., Fromentin, R., Trautmann, L., Chomont, N., Valente, S. T. The Tat inhibitor didehydro-cortistatin a prevents HIV-1 reactivation from latency MBio  2015 6:e00465-15  DOI:10.1128/mBio.00465-15  PMID:26152583  PMCID:PMC4495168
    • Mediouni, S., Jablonski, J., Paris, J. J., Clementz, M. A., Thenin-Houssier, S., McLaughlin, J. P., Valente, S. T. Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice Current HIV Research  2015 13:64-79  DOI:10.2174/1570162x13666150121111548  PMID:25613133  PMCID:PMC4416414
    • Jablonski, J., Clementz, M., Ryan, K., Valente, S. T. Analysis of RNA processing reactions using cell free systems: 3' end cleavage of pre-mRNA substrates in vitro Journal of Visualized Experiments : JoVE  2014 e51309  DOI:10.3791/51309  PMID:24835792  PMCID:PMC4030693
    • Mousseau, G., Clementz, M. A., Bakeman, W. N., Nagarsheth, N., Cameron, M., Shi, J., Baran, P., Fromentin, R., Chomont, N., Valente, S. T. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription Cell Host & Microbe  2012 12:97-108  DOI:10.1016/j.chom.2012.05.016  PMID:22817991  PMCID:PMC3403716
    • Mousseau, G., Valente, S. Strategies to block HIV transcription: Focus on small molecule Tat inhibitors Biology  2012 1:668-697  DOI:doi:10.3390/biology1030668  PMID:24832514  PMCID:PMC4009808
    • Valente, S. T., Gilmartin, G. M., Venkatarama, K., Arriagada, G., Goff, S. P. HIV-1 mRNA 3' end processing is distinctively regulated by elF3f, CDK11, and splice factor 9G8 Molecular Cell  2009 36:279-289  DOI:10.1016/j.molcel.2009.10.004  PMID:19854136  PMCID:PMC3068534
    • Valente, S. T., Gilmartin, G. M., Mott, C., Falkard, B., Goff, S. P. Inhibition of HIV-1 replication by elF3f Proceedings of the National Academy of Sciences of the United States of America  2009 106:4071-4078  DOI:10.1073/pnas.0900557106  PMID:19237569  PMCID:PMC2646627
    • Valente, S. T., Goff, S. P. Somatic cell genetic analyses to identify HIV-1 host restriction factors Methods in Molecular Biology  2009 485:235-255  DOI:10.1007/978-1-59745-170-3_17  PMID:19020830  PMCID:PMC3804074
    • Naghavi, M. H., Valente, S., Hatziioannou, T., de los Santos, K., Wen, Y., Mott, C., Gundersen, G. G., Goff, S. P. Moesin regulates stable microtubule formation and limits retroviral infection in cultured cells EMBO Journal  2007 26:41-52  DOI:10.1038/sj.emboj.7601475  PMID:17170707  PMCID:PMC1782362
    • Valente, S. T., Goff, S. P. Inhibition of HIV-1 gene expression by a fragment of hnRNP U Molecular Cell  2006 23:597-605  DOI:10.1016/j.molcel.2006.07.021  PMID:16916646
    • Hazan, U., Romero, I. A., Cancello, R., Valente, S., Perrin, V., Mariot, V., Dumonceaux, J., Gerhardt, C. C., Strosberg, A. D., Couraud, P. O., Pietri-Rouxel, F. Human adipose cells express CD4, CXCR4, and CCR5 receptors: a new target cell type for the immunodeficiency virus-1 FASEB Journal  2002 16:1254-1256  DOI:10.1096/fj.01-0947fje  PMID:12153994
    • Valente, S. T., Chanel, C., Dumonceaux, J., Olivier, R., Marullo, S., Briand, P., Hazan, U. CXCR4 is down-regulated in cells infected with the CD4-independent X4 human immunodeficiency virus type 1 isolate m7NDK Journal of Virology  2001 75:439-447  DOI:10.1128/jvi.75.1.439-447.2001  PMID:11119612  PMCID:PMC113936
    • Dumonceaux, J., Chanel, C., Valente, S., Quivet, L., Briand, P., Hazan, U. Mutations in the env gene of human immunodeficiency virus type 1 NDK isolates and the use of African green monkey CXCR4 as a co-receptor in COS-7 cells Journal of General Virology  1999 80:1975-1982  PMID:10466793
  • chapter

    • Mousseau, G., Mediouni, S., Valente, S. T. Targeting HIV transcription: the quest for a functional cure Future of HIV-1 therapeutics: resistance is futile?. 121-145. 2015  DOI:10.1007/82_2015_435  PMID:25731772  PMCID:PMC4409574
scroll to property group menus

Research

research overview

  • According to the latest statistics published by the UNAIDS/WHO in December 2007, 33.2 million people were living with the Human Immunodeficiency Virus (HIV). In 2007, 2.1 million people died as a result of the acquired Immunodeficiency Syndrome (AIDS). Although antiretroviral drugs have had a dramatically beneficial impact on HIV-infected individuals who have access to treatment, they have had a negligible impact on the global epidemic. Therapies for retroviral infections in humans now used in clinical practice have limitations in that they often only shorten the duration of disease symptoms or fail to completely eradicate the virus with viral replication and disease recurring after discontinuation of the drug therapy. Additionally, the emergence of HIV variants with drug-resistance is an ongoing clinical problem. Clearly having a larger repertoire of therapeutic agents would be beneficial for combating the HIV epidemic.

    Retroviruses, due to their limited genome size and content, require the assistance of multiple host cellular proteins at each step in their elaborate replication cycle. Host cells, in response, have evolved many mechanisms for inhibiting viral replication. We have taken a general approach to identify the molecular interactions occurring within a cell that are critical for viral replication, or genes that have evolved in mammalian cells to block viral replication. The discovery of cellular factors involved in retroviral replication and an increased knowledge of their mode of action may lead to important antiviral approaches in clinical settings as one could block the modified use without affecting cell viability.
scroll to property group menus

Teaching

advisees

  • graduate advising relationship

    • Mori, Luisa Patricia, Ph.D.  candidate, 2018 -
scroll to property group menus

Background

education and training

  • Ph.D. in Microbiology-Virology, University of Paris Diderot (Paris VII) 2002
  • M.S. in Biotechnology, De Montfort University , granted jointly by Hogeschool West- Brabant, Etten-Leur, Netherlands 1998
  • M.S. in MaĆ®trise Biochemistry, University of Paris Diderot (Paris VII) 1997
  • B.S. in Applied Chemistry, Biotechnology, New University of Lisbon 1996
scroll to property group menus

Contact

full name

  • Susana Tereno Valente

geographic location

  • Scripps Florida 

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support